|Last Update: 06/19/13 - 4:04 PM EDT|
|YTD Performance: 6.16%|
|Previous Close: $39.64|
|52 Week Range: $36.63 - $42.83|
|Oustanding Shares: 852,000,000|
|Market Cap: 33,500,640,000|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||15||15||16||15|
|Growth Rate (Year over Year)||-6.15%||1.41%||-5.71%||8.32%|
If you're overly cautious about biotech, you could incur some major opportunity costs.
TEVA was downgraded from Outperform to Market Perform, Wells Fargo said. Company is facing increased competition and price erosion in the generic market.
TEVA was downgraded to Hold, Canaccord Genuity said. $45 price target. Company turnaround is taking longer than expected.
Until we see a session close below 1498.25, a near-term change in direction is unlikely.
Keep an eye on M&A action in biotech.
Shares of TEVA now seen reaching $50, according to Credit Suisse. Estimates also cut, given the company's new guidance. Outperform rating.
TEVA was downgraded to Neutral from Buy, UBS said. $41 price target. Company's transition will take time.
These are quality stocks, and they’d be sure to fall on a military escalation with Iran.
Here's a quick roundup of earnings from stocks we've recommended. The news has been uniformly good.
In the healthcare sector, TMO and TEVA are well positioned to ride out the market’s current volatility.